MKI67 and central nervous system cancer: This study aimed to investigate the potential of pharmacokinetic parameters derived from the Ex-Tofts model and the DP model as biomarkers for identifying IDH mutation, 1p/19q codeletion status, and tumor cell proliferation (Ki-67 LI) in gliomas.